# Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema

> **NCT00682539** · PHASE4 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 71 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Bevacizumab (Avastin)
- **DRUG:** Triamcinolone
- **DRUG:** Sham
- **PROCEDURE:** Lucentis

## Key facts

- **NCT ID:** NCT00682539
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2016-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682539, "Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00682539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*